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Echinacea purpurea has long been used for the treatment and prevention of respiratory tract infections. 
The medicinal plant has originally been discovered by the Native American population, who squeezed the 
sap from fresh plant or chewed dried roots. Today, commercially available preparations vary greatly in 
terms of Echinacea concentration, manufacturing methods, plant parts used, et cetera.  This heterogeneity 
results in tremendously fluctuating bio-activities between products. Some of these products finally failed 
to show efficacy in large clinical studies raising principal questions about the value of the medicinal plant.    
Objectives 
The aim of this doctoral work was to explore in vitro and in vivo pharmacological effects, as well as clinical 
efficacy in prevention and acute treatment of respiratory tract infections for a single, phytochemically 
characterized and standardized Echinacea purpurea extract (Echinaforce®, EF).  
Methodology 
In vitro antiviral and anti-inflammatory (immune-modulatory) activities of EF were researched studying the 
most relevant respiratory pathogens including influenza, respiratory syncytial virus (RSV) or coronavirus 
(CoV) and using cytokine assays for interleukins IL-6 or IL-8 in airway epithelial cells. Test tube experiments 
were sought to be confirmed in organotypic tissues and upon peroral administration of EF ex vivo, whereas 
bio-availability of alkylamides in the extract was investigated to estimate systemic relevance. Two clinical 
studies aimed to investigate efficacy of EF for the treatment and the prevention of respiratory tract 
infections and subanalyses served to confirm above proposed pharmacological actions in vivo. Finally, EF’s 
therapeutic potential beyond its traditional use for colds and flu was researched by looking at the 
prevention of bacterial superinfections including bronchitis or pneumonia. 
Results 
EF was demonstrated to inhibit a wide range of respiratory agents, showing a primary specificity to 
enveloped viruses (e.g. influenza, RSV and CoV) in vitro and in a clinical prevention study. The extract 
modulated overexpression of inflammatory cytokines in epithelial cells and in the presence of respiratory 
pathogens. It is thereby expected not only to impact occurrence but also the symptomatic development of 
viral infections. Alkylamides were found to play a role in the systemic immune-modulation as bio-availability 
was demonstrated after peroral ingestion of EF.  
Next, EF was administered for the treatment of clinically diagnosed influenza (flu) to find non-inferiority to 
the gold-standard therapy Oseltamivir in this indication. Comparable recovery rates were observed for 
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virologically confirmed influenza infections, demonstrating clinical efficacy in the treatment of viral 
respiratory infections.  
Another large clinical study investigated EF for the prevention of respiratory tract infections. In the placebo 
group a total of 188 cold episodes were identified, which lasted for 850 days in comparison to 149 episodes 
and 672 sick days with EF extract (p < 0.05). Enveloped viruses (influenza, RSV and CoV) were found in 24 
patients with EF and in 47 with placebo (p < 0.05). 
In vitro EF reduced the expression of bacteria-binding receptors (e.g. of intracellular adhesion molecule, 
ICAM-1) on airway epithelial cells after infection with respiratory viruses. Thereby, EF prevented the 
attraction of pathogenic bacteria potentially inducing bacterial superinfections of initial viral infections.  
 
Conclusion 
The evidence generated by this PhD work substantiates the medicinal value of Echinacea purpurea for the 
treatment and prevention of respiratory tract infections. By focussing on a single, chemically standardized 
extract (Echinaforce®) problems with heterogeneity between Echinacea products could be overcome to 
reach more consistent conclusions. 
EF exhibits antiviral and anti-inflammatory effects to not only prevent occurrence but also the symptomatic 
development of infections. Alkylamides are bio-available and capable to systemically modulate the immune 
response. Bacteria-binding receptors on the epithelium are controlled with EF to finally prevent respiratory 







Aims and Objectives 
 
The aim of this doctoral work was to explore in vitro and in vivo pharmacological effects, as well as clinical 
efficacy in prevention and acute treatment of respiratory tract infections for a single, phytochemically 
characterized and standardized Echinacea purpurea extract (Echinaforce®, EF).  
The following aims and objectives were to be achieved and answered for Echinaforce® (EF) extract within 
this PhD work:  
- Exploring the antiviral activity in vitro  
- Exploring the anti-inflammatory (immune-modulatory) activity in vitro  
- Confirming antiviral and immune-modulatory actions in vivo and ex vivo 
- Assessing bioavailability of alkylamides after peroral administration of EF extract 
- Assessing clinical efficacy of EF extract in preventing RTIs  
- Assessing clinical efficacy of EF extract in treating influenza illness  
- Assessing the potential of EF extract in preventing RTI complications (bronchitis or pneumonia) in 
vivo while  
- Exploring the underlying mode-of-action for prevention of RTI complications in vitro 
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Original Contribution to Knowledge 
 
The evidence accrued in this PhD work materially contributes to the modern scientific understanding of 
Echinacea purpurea and substantiates its medicinal value for the treatment and prevention of respiratory 
tract infections. By focussing on a single, chemically standardized extract (Echinaforce®) problems with 
Echinacea products’ heterogeneity could be overcome to achieve more consistent conclusions. 
The provided in vitro and in/ex vivo results suggest antiviral, anti-inflammatory and immune-modulatory 
activities. Two clinical studies were carried out demonstrating efficacy in the prevention and treatment of 
respiratory tract infections under randomized, double-blind, placebo-/active controlled conditions. Finally, 
EF showed potential in preventing bacterial complications of initial viral infections through regulation of 
bacteria-binding receptors on epithelial cells. 
Maybe the most relevant outcome of this PhD work presents the unspecific activity of EF against a broad 
range of enveloped viruses. The current Covid-19 pandemic shows that nature harbours a plethora of 
pathogens for which the medical armamentarium has no immediate solution. Infections can globally spread 
within weeks and effective vaccines or therapies are not timely available. Readily accessible herbal 








Herbal medicine has always been essential in health care and today still plays an important role in the 
treatment and prevention of illnesses (Piletti et al., 2001). In antiquity no distinction between food, food-
supplements, spices and therapeutic agents was found - nutrition and medicine were not seen as strictly 
separate entities (Fürst and Zündorf, 2015; Engebretson et al., 2002). Today, this distinction is very well 
developed and established as a scientific and political paradigm. Unprocessed plants may still be used as 
part of nutrition but preparations thereof fall into a tightly regulated sector of “plant-products”. Even more 
so if they are declared as being used for medicinal purposes with specific indications and therapeutic claims, 
i.e. herbal medicinal products (HMPs, Gupta, 2015). 
Such herbal medicinal products may gain market access (registration or licence) as “medicines” if produced 
and vended in compliance with internationally applicable standards (Pharmacopoea Europaea, Ph.Eur.) and 
monographs issued by the European Medicine Agency (Herbal Medicinal Product Committee, HMPC). A 
majority of HMPs achieve the level of a traditional HMP (THMP) due to a “plausibility” of efficacy as 
evidenced by 30 years in-use rather than any sound clinical evidence (Cox and Roche, 2004). As a 
consequence, many questions and uncertainties pertaining to pharmacology and effectiveness remain, 
leading authorities and medicine agencies to implement increasingly cautious restrictions regarding the use 
of plant-products due to lack of evidence.  
For example, the HMPC (a subsection of the European Medicine Agency, EMA) granted registrations for the 
purple coneflower [Echinacea purpurea (L.) Moench] under the following precondition only (HMPC, 2015): 
- Preventive continuous use of maximal 10 days   
- No use in paediatric population 
- Autoimmune illnesses stated as a contraindication 
Limitations were introduced because of open questions concerning safety / pharmacology (e.g. Echinacea 
as a potential pure immune-stimulant), lack of data on use in children on the one side, and on the other 
side only limited evidence regarding its efficacy (Kreft and Razinger, 2014). For instance, the assessment 
report argues that beyond a duration of 10 days treatment efficacy was not proven convincingly, which 
would be an essential requirement for granting extension. In contrast, earlier monographs by the European 
Scientific Cooperative on Phytotherapy (ESCOP) or by World Health Organization (WHO) more closely 
stayed with the historical medicinal use of this plant with a maximal duration of use of eight weeks and no 
limitations in the paediatric population (WHO, 1999; ESCOP, 2009). In essence, the example demonstrates 
the importance of scientific research in preserving the historical use of herbal medicinal products and to 




1.1 History and Therapeutic Use of Echinacea 
The medicinal properties of Echinacea have originally been discovered by the indigenous population 
Americas (Bauer and Wagner, 1990). They mainly used Echinacea purpurea (L.) Moench, E. pallida (Nutt.) 
Nutt. and E. angustifola DC. var. angustifolia, all of which belong to the Compositae/Asteraceae plant family 
(Riddel, 1835; Mitchel, 1909 and WFO, 2020). Geographically completely distinct ethnic groups 
independently discovered very similar medicinal uses. Anaesthetic and anti-inflammatory actions were 
found beneficial not only for the treatment of cold-related symptoms like sore-throat but also for 
toothaches and snake bites (Wishart, 2007).  
In the beginning of the 20th century eclectic physicians primarily used E. angustifolia roots for wounds, 
poisonous bites, stings and acute infections, even for sepsis as a “corrector of body fluids” (Felter, 1906 and 
Felter, 1989). Despite condemnation of Echinacea in 1909 by the American Medical Association of being 
unworthy of further consideration until more reliable evidence is present in its favour, Echinacea continued 
to be very popular and ranked first in sales statistics of Lloyd Brothers Inc. (Puckner, 1909; Lloyd, 1923 and 
Lloyd, 1917).   
E. purpurea had not seen similar appreciation in Europe until the Swiss naturopath Alfred Vogel and Gerhard 
Madaus imported seeds from this species (Bauer and Wagner, 1990). With its introduction in Europe in the 
early fifties and the subsequent large-scale production, the today still dominant players were introduced in 
the pharmacy market: Echinaforce®, a hydroalcoholic extract (65% V/V) of E. purpurea herb and roots (95:5) 
by A. Vogel AG, Switzerland and Echinacin®, a hydrophilic pressed juice from E. purpurea herb (Madaus 
GmbH, Germany). Today, both E. purpurea and E. angustifolia are not listed in the International Union for 
Conservation of Nature’s Red List of Threatened Species (IUCN, 2020). 
Regardless of the broad historical use of Echinacea for a wide range of ailments, scientific research 
commenced exploring potential benefits in respiratory tract infections more specifically. In consequence, 
authoritative textbooks published by the HMPC, WHO and ESCOP mention beside the topical use for 






1.2 Echinacea Product Heterogeneity 
As shown by Gilroy and colleagues (2003), commercially available products containing Echinacea vary 
considerably in terms of  
- plant species used (E. purpurea, E. angustifolia or E. pallida)   
- source material quality (fresh, dried or lyophilized),  
- plant parts used (above-ground herb and/or roots, whole plant) 
- manufacturing techniques (dried powder, tea, alcoholic extractions, CO2 extracts or pressed-juice) 
An incredible heterogeneity results within available Echinacea products and their content of bio-active 
substances, which has analytically been investigated using High Performance Liquid Chromatography 
(HPLC) technique (Osowski et al., 2000; Tobler et al., 1994). The fact that some Echinacea preparations were 
given intra-muscular or intra-venously further complicates the comparability of products and undermines 
any general conclusion on efficacy for the medicinal plant (Barnes, 2005).  
When considering the quality of Echinacea products a few classes of chemical markers are discussed to be 
pharmaceutically important (Bauer and Wagner 1990). Those comprise the caffeic acid derivatives 
echinacoside, verbascoside, cichoric and chlorogenic acid, or cynarin, flavonoids (e.g. quercetin, luteolin), 
aetheric oil, asteracea-specific polyacetylenes, polysaccharides, whereas alkylamides or echinacoside are 
relatively specific for the genus Echinacea and cichoric acid for the species E. purpurea. The latter were 
suggested as reliable markers to approach the quality of Echinacea within its particular indication and use 
(Bauer, 1995; Bauer and Wagner 1990; Barnes, 2005).    
A systematic analysis of cichoric acid and alkylamides (e.g. dodeca-2E,4E,8Z,10E/Z tetraenoic acid 
isobutylamide, abbreviated as “tetraene”) found significant differences between plant species and plant 
parts used, lipophilicity of extractant and finally the underlying manufacturing process (Osowski et al., 
2000). Tetraene concentration amongst spagyric / homeopathic dilutions often ranged below the detection 
limit (<0.1 µg/ml) whereas mother tinctures contained reasonable amounts between 2.2 and 60.5 µg/ml.  
Significant differences were even found within preparations, which are both proposed by the HMP 
Committee for the treatment of respiratory tract infections: hydrophilic pressed juices and lipophilic 
hydroalcoholic extractions (both derived from E. purpurea) yielded concentrations as low as 1.1 µg and up 
to 60.5 µg of tetraene per ml, respectively. Very similar quantitative variations resulted from the analysis 
of cichoric acid. 
Bacterial impurity is another factor to be considered when assessing quality and pharmacology of natural 
products, in particular of Echinacea. Pugh and colleagues (2013) showed that macrophage activation 
observed in vitro was largely attributed to bacterial Braun-type lipoprotein and lipopolysaccharides (LPS) 
contained in certain Echinacea products. Similar biological effects were identified also for endotoxins, which 
seem to be quite abundant in preparations (Gertsch et al., 2004).  
16 
Doctoral_Work_Roland_Schoop31122020_vs10 
Impurities should be regarded critically as they tend to produce immune-stimulatory effects in vitro, 
including induction of inflammatory mediators TNF-alpha or interleukins (Ulevitch et al., 1995). These 
effects most reasonably should be classified as artefacts, because plant-derived products may contain these 
substances even if they are not taken for treatment of respiratory tract infections. Essentially, impurities 
are not Echinacea-specific but rather depend on or are introduced by manufacturing processes. Important 
articles even have pointed out that any unspecific induction of inflammatory meditators (e.g. TNF-alpha or 
IL-6) may produce adverse effects in acute respiratory infections, which themselves are the symptomatic 
manifestation of inflammatory processes (Johnston, 1997). 
 
Overall, it can be concluded that Echinacea preparations vary considerably, quantitatively as well as 
qualitatively. This is inevitably resulting in diverging in vitro bioactivities and might therefore present a 
reasonable justification for heterogeneities observed in clinical trials results as well (Karsch-Völk et al., 
2014). 
 
1.3 Research on Echinacea and Plant Extracts in General 
As exemplified by author instructions of scientific journals (e.g. Phytomedicine or Planta Medica), research 
on plant products increasingly abstains from investigating unspecific bio-activities or substances that are 
widely abundant and probably ingested at higher quantities from other sources (i.e. polyphenols). Anti-
oxidative, radical-scavenging or antiproliferative effects are not of primary interest for investigating 
Echinacea within its indication. Concentration is another critical parameter for the judgement of 
(physiological) relevance of observed in vitro effects. Bio-active substances in herbal preparations often 
demonstrate limited bioavailability and it is recognized that effects at concentrations above 100 µg/ml are 
not likely to be of physiological relevance (Epriliati and Ginjom, 2012). 
Below biological activities are currently discussed as determinants for the therapeutic potency in preventing 
and treating respiratory tract infections, for which Echinacea is taken. Even when focusing on these more 
relevant assay systems, the available literature continues to show great heterogeneity between products 
mentioned above.  
 
1.3.1 Anti-viral Effects 
A review by Hudson and Vimalanathan (2011) identified for most Echinacea species and products antiviral 
effects in vitro, but for some only at elevated concentration, i.e. above 100 µg/ml (Hudson and 
Vimalanathan, 2011). Wacker and Hilbig found a 50 – 80% protection against infections by herpes simplex 
virus (HSV-1), influenza A or vesicular stomatitis viruses (VSV) when pre-treating cell lines for 4 - 6 hours 
with either aqueous or methanolic E. purpurea extracts. Concentrations of 20 µg/ml showed significant 
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effects, the “protection” persisted for 24 hours and could be reversed by the addition of hyaluronidase 
enzyme (Wacker and Hilbig, 1978). Echinacea was proposed to transform cells into a virus-resistant state 
through the induction of interferons (e.g. IFN-γ) as shown by mice in vivo experiments by Bodinet and 
colleagues / Zhai and colleagues (Bodinet et al., 2002; Zhai et al., 2007).  
Results complemented earlier findings from May und Willuhn (1978) that demonstrated for E. pallida 
aqueous extracts, direct virus inhibition at a concentration of 27 µg/ml. Results also resemble data obtained 
from E. purpurea pressed juice and Cheminat and colleagues suggested caffeoyl-derivatives (e.g. caffeic and 
cichoric acid) as active players in hydrophilic preparations (Cheminat et al., 1988). However, cichoric acid 
was found to inhibit 50% infectivity only at concentrations of 125 µg/ml, raising the question of 
physiological relevance of those findings. Others have, in contrast, postulated the importance of lipophilic 
extraction (i.e. hexane or ethanol) of E. purpurea for optimal inactivation of herpes simplex virus (Binns et 
al., 2002). A minimal 100% inhibitory concentration (MIC100 value) against HSV and influenza was found in 
the low microgram range for aqueous and ethanolic extracts. Cichoric acid was attributed an at least 
moderate activity. Vimalanathan and colleagues finally investigated several solvent fractions from E. 
purpurea to find most impressive anti-influenza and anti-HSV activity in an ethyl acetate fraction upon light 
activation. Polysaccharide-enriched fractions (hydrophilic) showed a relatively weak activity in the same 
experimental setting (Vimalanathan et al., 2005). 
In conclusion, the medicinal plant Echinacea principally provides a rich source for antiviral substances, 
which are however not completely retrieved by all manufacturing procedures. On the other side, a clear 
correlation of antiviral activity with any particular substance classes cannot be made based on the available 
evidence. Comparison of the available literature is hampered by methodological differences and the high 
variability in Echinacea sources and specimen preparations.  
 
1.3.2 Anti-inflammatory Effects 
Inflammation represents the by-product of a pathogen eliminating process called immune response. It is 
the result of an excessive production of pro-inflammatory mediators (acute phase proteins) including tumor 
necrosis factor alpha (TNF-α) or interleukins (IL-1 and IL-6). It has been shown that the severity of 
respiratory symptoms tightly correlates with the production of mentioned mediators in the airways and 
their regulation may represent a mechanism for effective treatment (Johnston SL, 1995). Also, in this 
respect different Echinacea preparations produced different effects as briefly outlined in the following and 
more extensively elsewhere (Barnes, 2005). 
In vitro an endotoxin-free E. purpurea pressed-juice (herba) and purified polysaccharides thereof possessed 
immunostimulatory activity to murine and human macrophages and mononuclear cells as evidenced by 
induced TNF- α and interleukin levels (Burger et al., 1997, Stimpel et al., 1984). A dried E. purpurea extract 
activated production of TNF‐α, IL‐1 and IL-6 by natural killer cells obtained from human peripheral blood 
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mononuclear cells (hPBMCs) and enhanced the phagocytic activity (See et al., 1997). Rininger (2000) found 
clear stimulation of TNF-α and IL-6 in RAW264.7 macrophages and hPBMC only upon simulated (in vitro) 
digestion of E. purpurea herb and root priorly dissolved in dimethyl sulfoxide (DMSO). However, different 
Echinacea preparations (laboratory and commercial) showed great effect variations in this experiment. 
Interestingly, extracts standardized to discussed marker substances like phenol contents (4%), 
polysaccharides or to echinacoside/alkylamide proved inactive in induction of said cytokines (Rininger et 
al., 2000). Roesler et al. (1991) postulated immunostimulatory effects in vivo but only upon bypassing 
digestion via intraperitoneal administration.  These results exemplify how in vitro observed effects may not 
fully develop upon peroral administration due to digestive degradation or low bioavailability of potentially 
active substances. 
In sharp contrast, more recent studies found that an endotoxin-free, alcoholic E. purpurea extract alone did 
not induce TNF-α neogenesis but modulated its expression upon lipopolysaccharide or viral stimulation 
(Gertsch et al., 2004; Zhai et al., 2007). Although TNF-α mRNA transcription was induced by Echinacea, its 
translation into TNF-α protein was not affected and protein secretion balanced. Here, alkylamides seem to 
play an important role in regulating inflammation through modulation of TNF-α, beside their known 
inhibition of cyclooxygenase and 5-lipoxygenase (Wagner and Jurcic, 1991). Likewise, Randolph et al (2003) 
found a general cytokine mRNA induction in vitro but a reduced production of IL-1β, ICAM-1, IL-8 and TNF-
α and concomitant increase of interferon IFN-γ upon 2 days oral administration of an endotoxin-free 
Echinacea preparation. Finally, Sharma and colleagues (2006) could in preliminary experiments identify 
intracellular activating effects of E. purpurea on STATS or NF-KB, some proinflammatory transcription 
factors.  
Overall, Echinacea effects on the immune system are qualitatively and quantitatively highly heterogeneous 
even somewhat contradictory. It appears that hydrophilic extracts (e.g. Echinacea pressed juices) may 
contain compounds which are able to broadly stimulate cytokine production at least in vitro. It remains to 
be ascertained, whether these substances are Echinacea-specific or rather ubiquitously abundant (i.e. 
polysaccharides or endotoxins). On the other side were lipophilic extracts (if free of endotoxins) able to 
more selectively modulate particular components of the immune system: typical inflammatory mediators 
(TNF-α or IL-1) were down-regulated by Echinacea in the presence of viral stimuli, whereas antivirally acting 
IFN-γ was purposefully upregulated. Finally, the phagocytic capacity was enhanced by lipophilic Echinacea 
preparations and contained alkylamides (Goel et al., 2002; Bauer et al., 1988).  
In conclusion, substances in Echinacea principally have demonstrable effects on cells of the immune system. 
However, results from in vitro tests do not fully match with in vivo experiments and are prone to artefacts 
as digestion, metabolism or bioavailability are not taken into account. Bacterial contamination and 
endotoxins may further blur interpretation of any Echinacea-specific effects. Despite those experimental 
short comings, Echinacea was until the beginning of the 21st century considered a pure immune stimulant, 
albeit a consistent direction of activation was not reliably documented.  
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1.3.3 Echinacea Clinical Results 
In view of Echinacea products’ heterogeneity, it seems little surprising that clinical results vary as well. As 
mentioned earlier, in vivo research mainly focussed on the indication “treatment and prevention of colds 
and flu” and the long-proposed immune-stimulatory effect of the plant. A recent Cochrane-analysis by 
Karsch-Völk and colleagues (2014) looked at 10 prevention and 14 treatment studies of low (14), high (9) 
and unclear (1) risk of bias studying overall 4631 participants. The analysis concluded modestly positive 
effects for prevention overall (10 – 20%) and a tentative, exploratory pooling yielded a risk ratio of 
contracting a cold of RR = 0.83, 95% CI 0.75 to 0.92 (p< 0.001). Results on acute treatment effects were 
more consistent at least for Echinacea above-ground plant parts but not overall (Karsch-Völk et al., 2014). 
The parameter “sum scores after 5 to 10 days of treatment” provided more convincing treatment benefits 
than “duration of colds”, which was reported in only two clinical studies (Karsch-Völk et al., 2014).  
A comparison with earlier Cochrane reviews shows that the past decade of research has not created enough 
evidence to overcome problems associated with heterogeneity (Linde et al., 2006). In 2005, the publication 
of a very large, methodologically sound clinical trial attained much attention in the public domain (Turner 
et al., 2005). The study found no significant benefits for three different E. angustifolia preparations for the 
prevention and treatment of rhinovirally induced clinical colds. This project was funded by the National 
Center for Complementary and Alternative Medicine (NCCAM) of the National Institute of Health and the 
associated press (AP) and Bloomberg Business News considered the result as the “nail in the coffin’ for 
Echinacea (Reuters, 2010). 
Turner and colleagues included a total of 437 subjects in the study but allocated them to eight different 
treatment arms. Thus, the relatively large sample was divided into small groups of less than 50 subjects. 
This sample size was finally too small to reach statistical significance. 
Consequently, Schoop (the author of this PhD work [2006]) and colleagues proceeded to analyse and 
identify further methodological weaknesses of above and of other available, non-significant studies and in 
their meta-analysis  
- pooled patient data in order to achieve greater sample sizes and more statistical power 
- defined the researched indication by introducing the cold definition by Jackson et al. (1958) and 
- focussed on methodologically high-level studies reaching Jadad-scores > 3 (Jadad et al., 1996) 
to finally find statistically significant effects in preventing cold episodes by Echinacea, despite the 
considerable variability in treatment effects between individual studies. The general perception of 
Echinacea being unworthy for further investigation was thereby refuted, but the fundamental question 
regarding the observed heterogeneity of treatment effects remained to be answered.  
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1.4 Research Strategy of Doctoral Work 
The 10 years of research retrospectively documented in this contextual statement aimed to explore in vitro 
and in vivo pharmacological effects, as well as clinical efficacy in prevention and acute treatment of 
respiratory tract infections for a single, phytochemically characterized and standardized Echinacea 
purpurea extract (Echinaforce® extract, abbreviated as “EF”). It was not the intention to find overarching 
conclusions regarding the plant but at least to overcome the repeatedly mentioned issue of heterogeneity 
for this particular Echinacea preparation.  
Echinaforce® extract is a hydroalcoholic tincture (65% V/V) from freshly harvested E. purpurea consisting 
of 95% herba and 5% radix, produced by A. Vogel AG, Switzerland. The plants are cultivated on proprietary 
fields at A.Vogel AG company (Switzerland) under organic growing conditions (according to the valid EC 
Directive). Cultivation, harvesting, storage, primary processing and documentation are in accordance with 
the Guideline on Good Agricultural and Collection Practise (EMEA/HMPC/246816/2005). The grower’s 
certification organization is BIO-SUISSE. The seeds are propagated at A.Vogel AG, using a wild type that has 
been self-propagated since at least the early 1950s. Identity of produced plant material is tested according 
the European Pharmacopoeia (Ph. Eur.) release by the European directorate for the quality of medicines & 
healthcare (EDQM) to ensure the identity of plant species used (EDQM, 2004). The extract shows a 
composition of known pharmacologically active marker substances, which is given in below table 1. As per 
product analysis sheet the extract is demonstrated to be free of impurities and endotoxins (i.e. 
lipopolysaccharides), which potentially could influence outcomes from bio-assays as mentioned in Section 
Echinacea Product Heterogeneity. 
Table 1: Pharmacologically active substances in Echinaforce® (EF extract), means of four determinations as obtained from 
[Sharma et al., 2009a]. PID 8/9 refers to dodeca2E,4E,8Z, 10E/Z tetraenoic acid-isobutylamide (“tetraene”). 
 
The aim of this PhD work was to explore pharmacodynamics of EF extract together with clinical health 
benefits using straight-forward techniques, while steering off the now known pitfalls in plant product 
research, like testing of bacterially contaminated specimen at too high concentrations using irrelevant 
assays (also see Section Echinacea Product Heterogeneity). Suitable bio-assays were selected to optimally 
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reflect the pathophysiology of viral respiratory tract infections in humans and with reference to expected 
points of actions upon peroral administration of EF extract as illustrated in figure 1 (Johnston, 1995).   
 
 
Figure 1 Pharmacological points of action controlling respiratory tract infections.  Respiratory viruses (blue) attack epithelial 
target cells (red) in the nasopharyngeal region/lungs, whereas pathogenic bacteria can subsequently be attracted to the site 
of infection to produce complicated infections (light blue). The immune system (green) comprises different cell types found 
in the tissue, blood and lymph. Oral ingestion (especially sucking tablets) delivers EF extract (purple) first to pharyngeal 
epithelial cells, where antiviral (A) and anti-inflammatory effects (B) unfold. Thereafter, EF is swallowed for systemic 
resorption into the blood stream and the tissue to reach cells of the immune system (C).  
 
To this end, the antiviral research investigated a wide range of relevant and actual pathogens (Elliot and 
Fleming, 2009; A in figure 1). Immunological tests distinguished local (B in figure 1) from systemic actions 
(C in figure 1) by using epithelial cells and peripheral blood immune cells, respectively (Roitt et al., 1998). 
Figure 2 illustrates the overall research strategy on which test system was employed and how results were 






finally clinical results (3rd level) was sought to scrutinize biological relevance and consistency of findings. 
For this purpose, bioavailability and pharmacokinetic properties of pharmaceutically active substances 
were investigated. Finally, the work explored EF’s therapeutic potential beyond the traditional use for colds 
and flu and looked at the prevention of bacterial superinfections like bronchitis or pneumonia (Kenealy and 
Arroll, 2009). 
Figure 2: Research strategy for exploring the pharmacology of EF extract. Correlation of in vitro antiviral, immune-
modulatory effects (1st level) with in vivo/ex vivo results (2nd level) was to be explored and finally linked to clinical efficacy 
(3rd level). Relevant citations are indicated in brackets. 










The following aims and objectives were to be achieved and answered for EF extract, while referring to the 
respective publications given in the following (Section 1.5 List of Referenced Publications): 
 
- Exploring the antiviral activity in vitro [1,2] 
- Exploring the anti-inflammatory (immune-modulatory) activity in vitro [1,3,4] 
- Confirming anti-antiviral and immune-modulatory actions in vivo and ex vivo [4-7] 
- Assessing bioavailability of alkylamides after peroral administration of EF extract [6] 
- Assessing clinical efficacy of EF extract in preventing RTIs [7] 
- Assessing clinical efficacy of EF extract in treating influenza illness [8]  
- Assessing the potential of EF extract in preventing RTI complications in vivo [7] while  










Prevention and Treatment 











1.5 List of Submitted Publications 
 
The following pivotal publications form the core of this PhD work, full texts are attached in the Annex. 
Citations to below publications in the text are highlighted in bold and underlined letters. 
Sharma, M., Anderson, S.A., Schoop, R., Hudson, J.B. (2009a). Induction of multiple pro-inflammatory cytokines 
by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. Antiviral 
Research, 83(2), 165-70. Cited in tables and figures as [1]. 
Pleschka, S., Stein, M., Schoop, R., Hudson, J.B.  (2009). Anti-viral properties and mode of action of standardized 
Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 
(S-OIV). Virology Journal, 6, 197. Cited in tables and figures as [2]. 
Sharma, M., Schoop, R. and Hudson, J.B. (2009b). Echinacea as an antiinflammatory agent: the influence of 
physiologically relevant parameters. Phytotherapy Research, 23(6), 863-7. Cited in tables and figures as [3]. 
Sharma, M., Schoop, R., Hudson, J.B. (2010). The efficacy of Echinacea in a 3-D tissue model of human airway 
epithelium. Phytotherapy Research, 24(6), 900-4. Cited in tables and figures as [4]. 
Ritchie, M.R., Gertsch, J., Klein, P., Schoop, R. (2011). Effects of Echinaforce® treatment on ex vivo-stimulated 
blood cells. Phytomedicine. 18(10), 826-31. Cited in tables and figures as [5]. 
Woelkart, K., Marth, E., Suter, A., Schoop, R., Raggam, R.B., Koidl, C., Kleinhappl, B., Bauer, R. (2006). 
Bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interaction with the immune 
system. International Journal of Clinical and Pharmacological Therapies, 44(9),401-8. Cited in tables and figures 
as [6]. 
Jawad, M., Schoop, R., Suter, A., Klein, P., Eccles, R. (2012). Safety and Efficacy Profile of Echinacea purpurea to 
prevent common cold episodes: A randomized, double-blind, placebo-controlled trial. Evidence Based 
Complementary and Alternative Medicine, 841315, Epub 2012, Sep 16. Cited in tables and figures as [7]. 
Raus, K., Pleschka, S., Klein, P., Schoop, R., Fisher, P. (2015). Effect of an Echinacea-Based Hot Drink Versus 
Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority 
Clinical Trial. Current Therapeutic Research, 77, 66-72. Cited in tables and figures as [8]. 
Vimalanathan, S., Schoop, R. and Hudson, J. (2017). Prevention of influenza virus induced bacterial 
superinfection by standardized Echinacea purpurea, via regulation of surface receptor expression in human 
bronchial epithelial cells. Virus Research, 233, 51-59. Cited in tables and figures as [9].  
 
Essentially, experiments were designed and carried out to explore in vitro and in vivo pharmacology of 
Echinacea purpurea. The work aimed to understand and estimate Echinacea’s medicinal value for the 
treatment and prevention of respiratory tract infections. By focussing on a single, chemically standardized 
extract (Echinaforce®) problems with Echinacea products’ heterogeneity were to be overcome, in order to 
achieve more consistent results. 
A basic knowledge on the pathology of respiratory tract infections and challenges for therapy is 





1.6 Respiratory Tract Infections (RTIs) 
Respiratory tract infections (RTIs) like colds and flu represent the most frequent illnesses in Western 
civilization (Rotbart and Hayden, 2000). Infections present with a variety of symptoms, including nasal 
complaints (sneezing, congestion or runny nose), sore throat, coughing as well as systemic symptoms like 
shivering, malaise, headache and sometimes fever.  Most colds and flus are self-limiting illnesses and 
recovery is expected within 7 – 10 days but sometimes residual coughing can persist for up to 2 -3 weeks 
(Fendrick, 2003; Aherne et al., 1970). In children below 5 years of age, RTIs represent the leading cause of 
mortality (Denny, 1995). An estimate of cost of illness in the United States shows that non-influenza illness 
ranges amongst the 10 most expensive diseases with 40 billion dollars annually spent for medication, 
working absences and doctor’s visits (Fendrick, 2003). Influenza certainly represents a unique viral illness 
amongst RTIs seasonally producing excess morbidity and mortality mainly in the elderly (Treanor and Falsey, 
1999). The World Health Organization estimates 25 to 50 million influenza infections, 150’000 
hospitalizations and up to 40 000 fatal outcomes every year in the United States alone (Fleming, Elliot and 
Nguyen-van Tam, 2009) 
1.6.2 RTI Complications 
RTIs have debilitating effects on our immune defence and tend to recur or exacerbate. Approximately 20 - 
30% of infections develop into complications, and an increased incidence is observed in COPD patients, 
children and in the elderly – basically in those with weak immune defences (Kaiser et al.,2003; Kenealy and 
Arroll, 2009). RTI complications include Otitis media, Tonsillitis, Sinusitis, Bronchitis, Bronchiolitis and even 
life-threatening Pneumonia. The fear of complications is the main motive for prescription of antibiotics by 
physicians because these conditions are frequently associated with bacterial super-infections of the 
originally viral illness (Kenealy and Arroll, 2009; Elliot and Fleming, 2009).  
1.6.3 Pathogenesis and Treatment of RTIs 
RTIs are caused by a wide variety of viruses, while Rhinovirus, Coronavirus, Respiratory Syncytial Virus (RSV), 
Metapneumovirus (MPV), Boccavirus, Parainfluenza (PI) and Influenza constitute 90% of colds and flu (Elliot 
and Fleming, 2009). It is impossible to timely identify the causative agent during acute illness without quick 
bed-side virus testing to adapt therapy. Only Influenza and to a certain degree RSV show a distinct window 
of appearance and a characteristic symptomatic picture to allow identification solely on basis of clinical 
diagnosis. In practice, treatment of RTIs thus aims at reducing inflammatory responses by the host to the 
viral infection and to reduce specific symptoms like cough (mucolytic and/or cough suppressants) or nasal 
complaints (decongestants).  
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Vaccination provides an effective means of combating infections by influenza but there are currently no 
agents to protect against other respiratory viruses. The development of a specific prophylactic against colds 
and flu is ultimately hampered by the multiplicity of viruses and their propensity to mutate. 
An alternative approach would be to support the body’s own immune mechanism, falling back on the 
principle that the human organism is able to defend itself naturally against viruses and bacteria. It is here, 
that Echinacea has ever played a unique therapeutic role (Barrett et al., 2003).  
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2 Pharmacology of Echinacea: Summary of PhD Pivotal 
Research Work 
 
The following section reviews the body of research carried out by the candidate to explore the (pre-) clinical 
pharmacological profile of Echinacea (on the example of EF extract). As shown in figure 1 the provided 
evidence is grouped into three levels 
1. Level: Basic in vitro research work,  
2. Level: Secondary confirmation by ex vivo, in vivo and bioavailability assays and finally  
3. Level: Clinical research data to correlate pharmacology with patient-reported outcomes  
in order to achieve the aims and objectives as set out in section Research Strategy of Doctoral Work.  
The applicant has mainly been involved in the conceptualization of study designs and project lead. He 
developed the overall research idea and strategy. He has made essential contributions to study protocols, 
evaluation, interpretation and publication of study results. His contribution to the respective research work 
is estimated giving percentage indicating the approximate proportion of resource (time). A detailed listing 
of inputs to the cited articles is included as Appendix 1 to show the range of contributed work. A brief 




2.1 Antiviral Activity of Echinacea purpurea 
The predominance of viruses in cold and flu infections has been outlined earlier (Rotbart and Hayden, 2000; 
Fendrick, 2003). A main scope of the applicant’s research thus focussed on the antiviral activity of EF extract 
as explored in more depth in the two pivotal scientific articles and a supplementary poster outlined below 
[Sharma et al., 2009; Pleschka et al., 2009; Signer et al., 2020]. The research question to be answered was 
whether EF extract would exhibit antiviral activity and at what concentrations, which marker substances 
are important and whether it would exhibit any specificity towards particular pathogens, including newly 
occurring virus strains. Employed techniques adhered to well-established methods for testing antiviral 
activities of pharmaceuticals and are detailed in the referenced publications. 
2.1.1 Antiviral Research 
 [1] Sharma, M. et al. (2009a). Antiviral Research, 83(2), 165-70. 
The applicant designed, initiated and guided the research project, helped with interpretation of results and writing of 
publication (parts on in vivo relevance and correlation with clinical evidence). His contribution to the overall work: 15 – 25% 
(exclusively intellectual input) 
In this first study, a wide variety of respiratory viruses was investigated for their sensitivity against EF 
extract.  
Antiviral activity was found against influenza A (H3N2), respiratory syncytial virus (RSV) and herpes simplex 
virus (HSV) at minimal inhibitory concentrations of MIC100 < 50 µg/ml. Activity against the most common 
rhinovirus was observed at higher concentrations of 800 µg/ml, which was still considered relevant upon 
topical application (sucking, gargling) to the pharynx region (Sharma et al., 2009). Very recent research data 
completed investigations on anti-viral activity of EF extract with data on coronaviruses [CoV-229E, CoV-
MERS and CoV-SARS] and parainfluenza viruses, to show high sensitivity to the extract at inhibitory 
concentrations of IC < 50 µg/mg as well (Signer et al., 2020).  
The generated evidence nourishes the hypothesis that EF extract may have antiviral potential to broadly 
block membranous, rather than non-membranous viruses like adenoviruses or poliovirus (Sharma et al., 
2009; Signer et al., 2020). The latter were less sensitive to the extract and only at concentrations above 800 
µg/ml. Results show, that direct exposure to the extract is mandatory for maximal inhibition, whereas the 
addition of EF after viral inoculation (“intracellular protocol”) produced a significantly weaker inhibition. 
The observed differences in activity called for the underlying mechanistic mode-of-action capturing 




2.1.2  Antiviral Research (Influenza) 
 [2] Pleschka, S. et al. (2009). Virology Journal, 6, 197. The applicant designed and guided the research work, in 
particular the resistance experiments. He coordinated the work/exchange between laboratories and was involved in writing 
of publication (Echinacea and in vivo relevance). Contribution to the overall work: 20 – 30% (exclusively intellectual input). 
Different influenza strains (A/Victoria/3/75; A/Thailand/KAN-1/2004, A/FPV/Bratislava/79, A/Puerto 
Rico/8/34 and A/Hamburg/1/09) were cultivated in MDCK cells or embryonated chicken eggs prior 
exposure to EF. Again, minimal inhibitory concentrations (MIC) were estimated at differing plaque forming 
units (pfu) to find that all influenza strains were susceptible to EF extract at concentrations of 0.1 to 50 
µg/ml. 
A hemagglutination assay investigated influenza’s ability to aggregate erythrocytes via interaction of viral 
docking receptor haemagglutinin (HA) with cellular sialic acid to form virus – erythrocytes precipitates. 
Already at 50 µg/ml EF prevented this agglutination, indicating that the extract modified influenza surface 
receptors (HA), which are essential for viral attachment to host cells during the infection process. The viral 
replication process was thus found affected by EF at the earliest possible step (prior to cellular infection) 
(Sharma et al., 2009). Intracellular virus replication was however not further influenced by the extract, or 
only at higher, probably non-physiological concentrations, as demonstrated for influenza or coronavirus 
(Sharma et al., 2009; Signer et al., 2020).   
We found that prolonged exposition of influenza to a neuraminidase inhibitor (Oseltamivir) produced the 
emergence of resistances, whereas continuous passaging in the presence of EF extract did not have the 
same effect. Obtained Oseltamivir-resistant influenza viruses finally kept their susceptibility towards EF 
extract (Pleschka et al., 2009). 
Interestingly, two research laboratories at the University of British Columbia, Canada (Sharma et al., 2009) 
and the University Giessen, Germany (Pleschka et al., 2009) have found varying inhibitory concentrations 
(IC50 and MIC100) for EF extract in inhibiting influenza. This might be due to altering viral 
infectiousness/concentration, i.e. plaque forming units (pfu). Whereas Pleschka and colleagues used stock 
solutions of 107 to 108 pfu, Hudson’s group used pfu’s ≤ 106 in their experiments. As already demonstrated 
by Pleschka et al. (2009) changing a virus pfu has implications on measured inhibitory concentrations, 
simply because more HA molecules need to be converted by more extract. Future research work should 
aim to standardize infectious units to make outcomes more comparable. Moreover, endpoints should be 
harmonized to express either IC50, MIC100 or to any other threshold. So far, experiments tested the direct 
virus blocking potential of EF as well as a treatment-like situation of administering EF to virally-infected 
cells. Further settings should include a prolonged (up to 72 hours) pre-treatment of target cells prior to viral 
infection to mimic a prevention-like situation. 
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The above cited work confirms the presence of antivirally active compounds in the medicinal plant E. 
purpurea. Particular extracts thereof (e.g. EF extract) show a specificity towards membranous respiratory 
viruses like Influenza, Respiratory Syncytial-, Herpes simplex, Corona- or Parainfluenza viruses. Due to the 
multiplicity of bio-active substances in herbal extracts, it is reasonable to assume that resistances are less 
likely to develop and activity is maintained over time (Wagner and Merzenich, 2009). Direct contact of virus 
and extract however is important to entail maximal biological activity, which advocates the use of Echinacea 
for prevention – i.e. prior to viral infiltration of host cells. Once infection has established EF extract is only 
partially or not effective in blocking replication intracellularly and only budding off-springs might be 
neutralized thereafter.  
  
2.2 Immune-modulatory Effects of Echinacea purpurea 
E. purpurea is widely used by consumers for the support of immune defences (Barrett et al., 2003). 
Functions of the immune system are however highly complex and depend not only on typical immune cells 
like T-, B-, dendritic cells but also on macrophages in their respective differentiation modes. RTI symptoms 
for instance are primarily a result of a local inflammatory response of airway epithelial cells to viral infection 
(Johnston, 1997). Clinical examinations have shown that the nasal production of cytokines like interleukin-
6 (IL-6, IL-8 or TNF-α) directly correlates with symptom severity and the course of infections (Grünberg et 
al., 1997). As a consequence, local anti-inflammatory actions at the site of infection (airway epithelium) 
effectively reduce the symptomatic evolution of cold and flu infections at an early stage. On the other side 
may systemic effects be different from locally applied, because here all kinds of immune cells are involved 
to build up primary and secondary immune responses, including immunological memory mainly during later 
stages of an infection (Roitt et al., 1998).  
We therefore aimed to explore the effects of EF extract on aspects of an immune response and 
differentiated local actions on epithelial cells from systemic actions on peripheral blood monocytes (PBMC). 
First, we investigated how and at which concentration EF extract affected the virally induced production of 
inflammatory IL-6, IL-8 and TNF-α by alveolar and bronchial epithelial cells. Time- and dose-dependence as 
well as specificity of effects were determined by varying exposure times, EF concentrations and viral stimuli. 
A common, well-established and valid technique (enzyme linked immunosorbent assay, ELISA) was 
employed, using most relevant target cells and respiratory agents in order to estimate expression profiles 
of important cytokines (see Section 1.3.2. Anti-Inflammatory Effects). Secondly, it was investigated if effects 




2.2.1 Immunological Research (in vitro) 
[1] Sharma, M. et al. (2009a). Antiviral Research, 83(2), 165-70. 
[3] Sharma, M., Schoop, R. and Hudson, J.B. (2009b). Phytotherapy Research, 23(6), 863-7.  
The applicant designed, initiated and guided the research project, helped with interpretation of results and writing of 
publication (parts on in vivo relevance and correlation with clinical evidence). His contribution to the overall work: 20 – 30% 
(exclusively intellectual input) 
Human alveolar epithelial (A459) and bronchial cell-lines (BEAS-2B) were cultivated in vitro prior to infection 
with rhinovirus (RV14 or RV1A). As expected, viral infection augmented the production of IL-6, IL-8 and TNF-
alpha, whereas EF dose-dependently reversed their expression levels after 24 and 48 hours. The experiment 
also showed that 20 to 40 µg/ml of EF extract was sufficient to down-regulate inflammatory processes 
secondary to virus infection. Since EF was administered after viral infection it is reasonable to assume that 
the extract would still work even when infection had already established (i.e. for acute treatment). The 
addition of EF could be delayed until 48 hours post infection and inhibitory effects on cytokines still 
prevailed.  
Local anti-inflammatory effects finally were reproduced employing alternating infectious stimuli: Influenza, 
RSV, Adenovirus types 4 and 11 and Herpes simplex virus (HSV). A highly consistent picture of viral induction 
and reversal by EF extract became evident, indicating a generally applicable mode-of-action. 
 
2.2.2 Immunological Research (ex vivo) 
[4] Sharma, M., Schoop, R., Hudson, J.B. (2010). Phytotherapy Research, 24(6), 900-4.  
The applicant designed and guided the research project, introduced EpiAirway tissue to the research group, and contributed 
writing of publication. His contribution to the overall work: 30%  
Above in vitro results were then to be confirmed in an ex vivo model using organotypic 3-D tissue model of 
human airway epithelium. The EpiAirwayTM tissue (MatTeck, Ashland, MA, USA) represents a histological 
reconstruction of human airway epithelium composed of epithelial cells from human donors, mucin-
producing goblet cells and mechanically functional cilia. Rather than using immortalized cell lines the 
EpiAirwayTM re-builds the natural human airway epithelium retaining tissue architecture and differentiation 
(Klausner et al., 2007). The model is essentially appropriate because in vivo expressed interleukins by 
airways resemble the expression pattern by this ex vivo assay (Message and Johnston, 2004). Astonishingly, 
RV infection did not affect the histology of epithelium, which corresponds well with the reported lack of 
lytical potential for this type of virus.  Again, the viral induction of inflammatory cytokines and of mucin was 
potently reversed by EF as measured by ELISA technique 24 and 48 hours post inoculation.  
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So far, no single chemical substances contained in EF extract were investigated in above experiments and 
it would be interesting and point of future research to understand, which ingredients are mediating said 
effects. Combination with a permeability test system (e.g. Caco-2) would deliver information whether bio-
active substances are systemically available after all.     
In conclusion, effects of EF on the airway epithelium were seen under in vitro as well as ex vivo conditions 
supporting the hypothesis of Echinacea acting as a potential local anti-inflammatory agent. This action is 
considered of high importance in view of the early inflammatory genesis of typical cold symptoms. In fact, 
inhibition of inflammation by Echinacea was also observed in vivo in the context of clinically induced 
rhinovirus infections (inoculation studies). Thereby, the development of symptoms (inflammation) was 
significantly reduced by Echinacea, rather than the infection (rhinovirus titers) itself (Schoop et al., 2006). 
Local anti-inflammatory effects were herewith ascertained and the next experiment addressed the 
question how EF extract influences aspects of the systemic immune system in vivo. To this end, the number 
and function of immune cells were measured by means of full blood counts and measuring 
cytokine/chemokine production during oral administration of EF extract.  
To this end, the Instant Leucocyte Culture System (ILCS®) was employed for leukocyte activation 
immediately upon drawing the blood from Echinaforce-treated subjects under standardized conditions. 
This was accomplished by using a peculiar type of blood-sampling syringe, pre-filled with cell culture 
medium, including already the stimulants used to activate leukocytes. This eliminated the need for any cell 
preparation and avoided artificial, undesired manipulation-dependent changes in cell behaviour. Moreover, 
the immediate activation upon bleeding prevented storage- and shipping-induced impairment of cell 
functions guaranteeing a maximum of standardisation. The sequence of a) drug ingestion and b) extra-
corporeal immune cell stimulation mimics also widely the events upon drug intake, where the drug first is 
absorbed in the intestine. Then the active ingredients occur in the blood and take effect on circulating 
leukocytes, which are later recruited to the diseased tissues, where finally their activation takes place. 
Stimulants were selected to activate essential receptors of the most important leukocyte subtypes 
differently involved in the regulation of immune responses and inflammation: lipopolysaccharide (LPS) and 
staphylococcal enterotoxin B (SEB, a so-called superantigen), excellently activating e.g. T-cells.  
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2.3.3 Immunological Research (in vivo/ex vivo) 
[5] Ritchie, M.R. et al. (2011). Phytomedicine. 18(10), 826-31. 
The applicant designed and guided the research project and implemented the Instant Leukocyte Culture System, ILCS®. He was 
involved in study set up, patient inclusion and informed consenting at the investigational site. Writing of publication 
(introduction/conclusion, parts on in vivo relevance and correlation with clinical evidence). His contribution to the overall work: 
40-60% (experimental and intellectual input) 
This study aimed to examine effects of peroral application of EF extract on ex-vivo stimulated PBMCs to 
localize any systemic effects. After a run-in phase of two days (baseline), EF was administered over eight 
days to 30 healthy individuals. Daily collected blood (isolated PBMCs) was stimulated with LPS 
(lipopolysaccharide, 100ng/ml) and SEB (staphylococcal enterotoxin B, 25ng/ml) for 24 hours using the 
Instant Leukocyte Culture System (ILCS®). EF increased production of chemotactic interleukin-8 (IL-8), MCP-
1 and reduced the expression of inflammatory TNF-α and IL-1 upon ex vivo stimulation. In consistency with 
an anti-inflammatory response, IL-10 was increased to baseline levels. Anti-virally acting interferon gamma 
(IFN-γ) was purposefully induced in volunteers with elevated risk of infection and in stressed subjects. 
Individuals with low cortisol levels (n = 11) experienced significant down-regulation of acute-phase proteins 
IL-1-beta, IL-6, IL-12 and TNF- α, while those with higher cortisol levels showed no such down-regulation 
upon treatment with EF. The respective numbers of immune cells (erythrocytes, leukocytes, neutrophils, 
lymphocytes, monocytes, eosinophils, basophils and thrombocytes) remained unchanged during 
treatment. This ex vivo trial suggests a support of weak immune systems by Echinacea, i.e. during phases 
of increased stress or susceptibility to cold infections, while well-performing immune systems are not over-
stimulated. Effects are best described as immune modulation. 
Effects were observed upon peroral application of EF extract using an ex vivo/in vivo approach and are in 
agreement with and further confirmation of anti-inflammatory effects seen in vitro [Sharma et al., 2009b 
and 2010]. Through elevated IFN-γ antiviral immune defences are supported and an increased MCP-1 and 
IL-8 production contributes the attraction of immune cells to the site of infection (chemotaxis).  
Results were generally afflicted by large standard deviations, as typically seen with this kind of ex vivo 
experiments. Often statistical significance was not reached for individual cytokines and particular treatment 
days necessitating a pooling of single measurement into a global analysis (whole treatment period). Also, 
no placebo control was included and reference was made to baseline. Future experiments may consider to 
include larger patient numbers to reduce variance of results and include a parallel control treatment. Also, 
it would be interesting to collect blood samples from infected rather than healthy subjects to gain results 
from an acute treatment scenario where figures might be different. 
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Earlier studies by Gertsch (2004) highlighted the importance of alkylamides (e.g. dodeca-2E,4E,8Z,10E/Z-
tetraenoic acid isobutylamides or “tetraene”) in this immune-modulatory process (Gertsch et al., 2004). 
Through interaction with the human endocannabinoid system, i.e. binding to cannabinoid receptor (CB-2), 
tetraene and its derivatives are able to modulate the production of TNF- α to provide a possible mode-of-
action for the effects observed by Ritchie (2011). The next set of experiments therefore aimed to clarify 
whether alkylamides are resorbed after all at detectable concentrations in blood serum for their purposed 
interaction with PBMCs. Galenic variations (drops, tablets) containing EF extract were ingested by healthy 
volunteers to determine kinetic profiles and levels of bioavailability by applying routine methods for 
bioavailability investigations. Another goal of the study was to re-confirm above mentioned effects on 
immunological markers ex vivo, again using the established ELISA technique mentioned in Section 2.2 
Immune-modulatory effects of Echinacea purpurea  
 
2.4 Immunological Research (Bioavailability and Pharmacokinetics) 
[6] Woelkart, K. et al. (2006). International Journal of Clinical and Pharmacological Therapies, 44(9),401-8. 
The applicant designed the research project, wrote study protocol and was involved in the registration process of the clinical 
study. Writing of publication (clinical and pharmacodynamics parts). His contribution to the overall work: 20-30% (protocol 
development and study setup) 
Dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide („tetraene“) was found to be bioavailable from 
E. purpurea in the form of EF tablets and tincture in a randomized, open, single-dose cross-over study 
involving 10 patients. Maximal concentration (Cmax) of tetraene was found to be 0.12 ng/ml after a dose of 
12 Echinaforce tablets and was reached after Tmax of 45 minutes. Cmax of the same marker substance after 
a dose of 4 mL Echinaforce tincture (EF extract) was found to be 0.40 + 0.11 ng/mL after 30 minutes. 
Tetraene levels returned to baseline within three to four hours (Woelkart et al., 2006).  
For reaffirmation of observed anti-inflammatory effects, PBMC were isolated from EF-treated subjects and 
stimulated with endotoxin (lipopolysaccharide, 100 pg/ml). After 23 hours of stimulation, supernatant was 
collected and a significant reduction of TNF-alpha was observed in contrast to IL-6, which remained 
unchanged. Results were therefore well in agreement with observations by Ritchie et al., (2011).   
A second study tested the bioavailability of another tablet formulation (Echinaforce Junior tablets) in 
comparison with above conventional Echinaforce tablets. For both formulations a very similar Cmax = 0.22 
± 0.15 ng/mL and 0.23 ± 0.16 ng/mL was reached and a comparable amount of marker substance „tetraene“ 
resorbed. Echinaforce Junior tablets, which galenically complex alkylamides (e.g. tetraene) by β-
cylcodextrine “molecular tubes”, seemed to release the analytical marker slightly slower. The time to 
34 
Doctoral_Work_Roland_Schoop31122020_vs10 
maximum concentration was reached after one hour, while for the prior formulation the time was 
approximately half an hour (Woelkart et al., 2008).  
In conclusion, local and systemic anti-inflammatory effects were identified for EF extract in vitro, which 
were confirmed by two independent in vivo / ex vivo assays. Bioavailability studies show that the immune-
modulatory substance “tetraene” is absorbed after oral application of various EF galenic forms to exert 
systemic immune-modulation. The latter includes anti-viral and chemotaxis-inducing effects to support the 
hypothesis of Echinacea as an immunologically active plant.  
In our experiments we focussed on the resorption of “tetraene”, the main alkylamide in EF extract but did 
not test derivatives thereof or other typical chemical markers mentioned in table 1. Little evidence is 
available on the bioavailability of caffeic acid conjugates (cichoric acid or echinacoside), which according to 
Matthias et al. (2005) do not cross the intestinal barrier in vivo. Finally, no evidence of bioavailability is 
known for other Echinacea chemical markers, which for this reason were not included.  
A third and major part of the body of evidence presented in this PhD work form two large clinical trials that 
were carried out to estimate preventive and acute treatment benefits of EF extract. The first clinical trial 
administered EF extract continuously over 4 months to investigate safety and efficacy of long-term 
prevention. The study also aimed to further confirm pharmacological actions of EF mentioned in Section 
2.1 to Section 2.4: Pathogen analysis in nasal secretions from patients with colds allowed for reconfirmation 
of anti-viral effects and by assessing individual’s immune status we aimed to re-demonstrate any tailored 
immune-modulation by EF extract as proposed earlier. 
Methods principally adhered to already published study protocols (as reviewed by Karsch-Völk, et al. 2014) 
whereas cold episodes were defined according to the definition by Jackson and colleagues (1958). This was 





2.5 Clinical Study on Prevention of RTIs by Echinacea (Clinical Research) 
[7] Jawad, M. et al. (2012). Evidence Based Complementary and Alternative Medicine, 841315, Epub 2012.  
The applicant designed the clinical study, wrote study protocol and patient diaries/case report files (CRF), was involved in the 
registration process and study setup. He was involved in clinical monitoring and finally statistical evaluation, writing of 
publication and study report. His contribution to the overall work: 30-40% (protocol development, study setup, analysis and 
interpretation) 
This randomised, double blind, placebo-controlled clinical trial investigated the safety and efficacy of EF 
extract prevention on N=755 subjects over 4 months of continuous use. Nasal secretions from participants 
with acute colds were analysed for the presence of Rhinovirus, Influenza, RSV, Corona-, Parainfluenza-, 
Adeno-, Bocca- and Metapneumovirus using RT-PCR technique. 
EF extract was found non-inferior to placebo with regard to adverse events, adverse drug reactions (ADRs), 
laboratory blood parameters and finally the assessment of tolerability. Allergic reactions, leukopenia or 
autoimmune diseases were not increased under Echinacea treatment. 
In the placebo group a total of 188 cold episodes were identified, which lasted for 850 sick days in 
comparison to 149 episodes and 672 sick days with EF extract (Chi-Square test, p<0.05). Echinacea reduced 
virally confirmed infections from 74 to 54, while membranous viruses like Influenza, RSV, Parainfluenza and 
Coronavirus were found in 24 patients with Echinacea and in 47 with placebo (Chi-Square test, p<0.05). 
Thereby, earlier observations of antiviral activity against membranous viruses were confirmed in vivo 
(Sharma et al., 2009; Sharma et al., 2010; Signer et al., 2020). 
Preventive effects were also seen on the level of recurring cold infections: 100 episodes observed in 43 
subjects with placebo were reduced to 63 episodes in 28 subjects with Echinacea, corresponding to a ratio 
of recurring infections of 1.59 (p=0.017).  
The preventive effect of EF was further studied in subjects who reported stress, while reaching >14 points 
on the perceived stress scale (PSS-10). Both, cold episodes and episode days were significantly increased by 
66.6% and 40.7% with placebo treatment (p<0.05). Similar results were seen in more susceptible individuals 
(reporting >2 colds/year, N=343), those with poor sleep (<8 hours sleep, N=160) and finally those who 
smoked, although the last population was very small with N=43 subjects (Schapowal, 2013).  
The primary variable in this study regarded safety rather than efficacy, which was evaluated descriptively. 
This could eventually be considered as a weakness, however, sample size analysis showed that the study 
was large enough and appropriately designed to estimate the preventive efficacy with sufficient power.  
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Data from this large clinical study provides sound evidence for the clinical relevance (3rd level) of in vitro/ex 
vivo observed pharmacodynamic actions (1st and 2nd level as per Figure 1). Firstly, efficacy of EF extract was 
demonstrated for the prevention of respiratory tract infections. Given the prevalence of viruses in RTIs, this 
result alone points towards an antiviral efficacy. This was effectively confirmed by a reduced number of 
viral infections in the EF group. A high specificity towards membranous viruses was again reported 
Immune modulation seems to play a central role in Echinacea’s mechanism of action. As shown by Ritchie 
(2011), EF extract modulates immune functions primarily in case of increased susceptibility and during 
phases of stress. Very similar effects were seen in this clinical trial, where preventive benefits were 
predominant in individuals with stress, sleeping disturbance or in smokers. In the latter groups, the 
difference (EF to placebo) in experiencing cold episodes ranged between 40 and 67% and was therefore 
higher than the 26% relating to the overall population.   
This clinical study suffered from the typical limitations of long-term prevention trials, where compliance of 
study subjects over 4 months cannot be fully guaranteed. Some participants did not report colds at all and 
it cannot be ascertained whether no infections occurred or whether those were simply not reported. A 
closer observation of participants would be warranted to monitor intake of study medication and reporting 
of infections to the study centre. In fact, the Jawad study provides no further substantiation of anti-
inflammatory effects because no immunological parameters were assessed in patients. Instead, clinical 
evidence can be retrieved from artificial rhinovirus infection studies, where Echinacea was able to prevent 
the inflammatory, symptomatic development of clinical colds rather than the virus infection rate (Schoopet 
al., 2006). In conclusion, pre-clinical and clinical evidence suggests EF extract as active immune-modulator, 
that specifically reverses virally-induced secretion of pro-inflammatory mediators on the one side and 
supports immune functions (i.e. chemotaxis or IFN-γ) where required.  
With its specificity to broadly inhibit influenza viruses in vitro, EF extract was consequently investigated for 
the treatment of flu by means of an active controlled, randomized, double-blind clinical trial (Raus et al., 
2015). This study aimed to show non-inferior of EF extract to the gold standard therapy, Oseltamivir 




2.6 Clinical Study on Acute Treatment of Flu by Echinacea (Clinical Research) 
[8] Raus, K. et al. (2015). Current Therapeutic Research, 77, 66-72.  
The applicant designed the clinical study, wrote study protocol, case report files and patient diaries, contributed to the 
registration process and study setup. He was involved in monitoring, statistical evaluation and finally writing of publication 
and study report. His contribution to the overall work: 30-40% (protocol development, study setup, analysis and interpretation) 
Overall, 473 patients with clinically diagnosed influenza (ICD-19-GM-2014 classification J11.1) were enrolled 
in the study, taken a nasal sample for virus analysis and were randomly allocated to receive either EF extract 
(in form of Echinaforce Hotdrink, also containing Sambucus nigra) or Oseltamivir (Tamiflu®) for 10 days 
treatment under blind conditions. The European Commission granted a marketing authorisation for 
Tamiflu® for the acute treatment of influenza, for which it is considered the gold standard therapy. This 
study was closely adapted to the large phase III clinical studies with Oseltamivir, which showed significant 
superiority over placebo. 
 The primary efficacy parameter of the study was the confirmation of non-inferiority of Echinacea compared 
to Oseltamivir in the proportion of recovered patients after 1, 5 and 10 days of treatment in the per-
protocol collective (PP). The rate of recovery from illness was equivalent in the two treatment groups. After 
one day of treatment 1.5% of patients with EF extract and 4.1% with Oseltamivir fully recovered. After 5 
days of treatment the rates of recovered patients increased to 50.2% and 48.8%, respectively. After 10 days 
90.1% and 84.4% of the patients with Echinacea and Oseltamivir recovered from illness, respectively. 
Very similar recovery rates were obtained from patients with virologically-confirmed influenza as for the 
whole study population, as included after clinical diagnosis (0% vs. 0% after 1 day; 45% vs. 42.9% after 5 
days and 95% vs. 76.2% after 10 days with Echinacea and Oseltamivir, respectively). This implies a high 
prevalence of influenza virus infections among the included study subjects (whole population) although the 
virus recovery rate with approximately 10% was fairly low, this maybe due to suboptimal sample handling 
or recovery limits.  
Individual influenza symptoms alleviated quickly with both treatments despite marginally higher baseline 
values in the Echinacea group at inclusion. Interestingly, recovery of influenza-lead symptoms (cough, 
headache, myalgia and feverishness) occurred slightly faster (trend) with EF extract than with Oseltamivir. 
Fever resolved within 2 days and there was no difference between therapies. Respiratory and gastro-
intestinal complications were lower with EF extract (2.46%) than with Oseltamivir (6.45%, p=0.076). 
Antibiotics were administered only in 2% of patients and no hospitalization occurred, while the total use of 
rescue-medication was similar in both groups. With respect to safety, EF extract proved superior to 
Oseltamivir, due to a reduced incidence of gastrointestinal complaints including vomiting. 
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No patients with underlying health conditions were included into the study and thus no implications on 
influenza risk populations can be made (i.e. immune suppression, hypertonia or pregnancy). Subjects 
between 12 and 70 years of age were included but any conclusion regarding the paediatric and senescent 
population might be poorly conceived due to low patient numbers.  
The here investigated product has been developed to further optimize treatment effects in a novel galenic 
form, Echinaforce® Hotdrink. Beside EF extract as active substance the formulation contains several 
excipients including concentrated sap from Sambucus nigra berries (elderberry) and citric acid. The syrup 
was to be diluted in hot water. This pharmaceutical form has been shown to contribute to the subjective 
impression on symptom alleviation, including nasal complaints, sore throat and cough (Sanu and Eccles, 
2008). Moreover have clinical studies shown efficacy in the treatment of colds and flu for Sambucus nigra, 
but the resulting evidence was still considered insufficient for establishing an HMPC monograph (Hawkins 
et al., 2019 and HMPC, 2014). Whereas from a patient’s perspective the addition of beneficial components 
to EF extract is definitely sensible it still raises the question to which extent the observed treatment effects 
can be attributed to EF extract. With this respect the present study provides evidence for treatment effects 
for this particular galenic EF formulation rather than the EF extract. Also, this particular work does not 
further unravel the issues associate with heterogeneity in Echinacea preparations.  
This clinical trial nevertheless further corroborates in vivo relevance (3rd level) of the in vitro observed 
antiviral activity of EF extract (1st level). Non-inferiority to the antiviral gold-standard Oseltamivir in 
confirmed influenza infections suggests a similar (antiviral) mode-of-action for Echinacea. This study does 
however not provide additional evidence of immune-modulatory action as special groups have not further 
been analysed.   
Of particular interest was the low RTI complication rate observed in both treatments. Respiratory infections 
like colds and flu have a tendency to develop into RTI complications, associated with sinusitis, bronchitis or 
pneumonia. Some respiratory viruses like influenza or RSV are known to impair the physical barrier of airway 
epithelium and to even down-regulate immune functions giving access to bacteria - finally leading to viral / 
bacterial superinfections. Staphylococcus aureus, Haemophilus influenza or Streptococcus pneumonia are 
common agents involved in pathological illness exacerbation.  
A recent meta-analysis showed that Echinacea may have a potential not only to prevent viral RTIs but 
bacterial complications thereof as well. Thereby, lipophilic extracts prepared from E. purpurea prevented 
approximately 50% of complicated developments of RTIs (Schapowal et al., 2015). The very latest 
publication aimed to mechanistically explain the reported benefits using an in vitro approach. It researched 
in more detail if and how EF extract would be able to prevent bacterial adherence to the airway epithelium 
secondary to viral infections. In this context, we tested the relevance of cell surface receptors in the binding 
behaviour of pathogenic bacterial strains.   
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2.7 Research on Prevention of Superinfections (in vitro) 
[9] Vimalanathan, S., Schoop, R. and Hudson, J. (2017). Virus Research, 233, 51-59.  
The applicant has given intellectual input in design and conduct of the study. He was involved in writing publication. His 
contribution to the overall work: 20-30%  
Human bronchial epithelial cells (BEAS-2B) were cultivated to confluence prior to infection with H3N2 
Influenza virus. After removal of inoculum, cells were treated for 48 hours with EF extract, which was 
thereafter removed. Then, cellular binding of Staphylococcus aureus or non-typeable Haemophilus 
influenza bacteria was measured. EF treatment of BEAS-2B at concentrations of 1:200 and 1:400 lead to a 
significant reduction of bacterial adherence to virus-infected cells. The proceeding experiment examined 
involvement of cellular surface receptors (ICAM-1, platelet activation factor (PAF)-receptor or fibronectin), 
which have previously been shown to play a role in bacterial binding. Indeed, EF down-regulated the 
expression of all three binding structures as shown by immunohistochemical staining. It was further 
demonstrated, that binding of S. aureus could specifically be inhibited through a monoclonal blocking 
antibody to ICAM-1, highlighting the importance of receptors in the pathological process of bacterial 
adherence.  
The experimental approach used in this study is relatively new and involves many handling steps, i.e. cell 
cultivation followed by viral infection and subsequent exposition to EF extract whereas bacterial adherence 
is examined as a last procedure. One experimental cycle takes several days until completion and thereby is 
affected by significant fluctuation. Results should thus be considered qualitatively rather than to 
quantitatively assess the exact extent of reduction. Nevertheless, the experiment provides a reasonable 





3.  Overall Discussion  
 
Medicinal plants are a rich source for potent bio-active substances and even the pharmaceutical industry is 
reverting to chemical scaffolds from nature for drug discovery (Newman and Gragg, 2012). Isolation of 
individual compounds and activities however seems not trivial and different extraction techniques yield 
products, which are hardly comparable. Decades of Echinacea research investigated highly heterogeneous 
products from variable species and plant parts, using differing extraction methods. As a result, overall 
conclusions on Echinacea-derived preparations remain vague, leading to much confusion about sense or 
non-sense in using it. The goal of this PhD work was therefore to accurately address pharmacology and 
clinical efficacy for a single E. purpurea extract (Echinaforce®) by employing state-of-the art scientific 
methods. The research focussed on test systems deemed relevant for the estimation of its potential in 
respiratory tract infection prevention and treatment: Antiviral, anti-inflammatory and immune modulatory 
effects were studied in vivo, ex vivo and under in vivo conditions. 
 
3.1 Antiviral Activity of EF Extract 
 
Results clearly indicate a broad antiviral potential directed against membranous viruses. Experiments were 
carried out at three independent research facilities:  
- University of British Columbia, Canada: Sharma et al., 2009 
- University of Giessen, Germany: Pleschka et al., 2009 and  
- Laboratory Spiez, Switzerland: Signer et al., 2020.  
Results were across laboratories highly consistent and were finally confirmed by a large clinical prevention 
trial conducted at the University in Cardiff (Jawad et al., 2012). Whereas in vitro experiments yielded 
significant results on the level of individual viruses, in the clinical study (Jawad et al., 2009) only the pooled 
result of membranous viruses gave p-values below 0.05. This was mainly a consequence of low sample 
numbers when breaking down to the single pathogen rather than a lack of effect. A very recent clinical 
study investigated EF extract in children (4 – 12y) and for the first time provided a significant reduction also 
on the basis of particular virus species (i.e. influenza) (Ogal et al., 2019). Rhino- just like adenoviruses seem 
to be more resistant to EF extract that could not reduce infections neither in spontaneously occurring nor 
in artificially induced RV infection studies. A meta-analysis by Schoop, however, identified a potential of 
Echinacea in reducing the symptomatic development, rather than the infectivity of RV pointing towards 
anti-inflammatory activity of the extract being of importance, too (Schoop et al., 2006). In a patient’s 
perspective it might be irrelevant whether prevention of RTIs is achieved through suppression of viral 
infection or simply of symptom development – since both would result in maintenance of health. 
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Rhinoviruses are not known to be particularly lytic nor to cause significant pathology to the respiratory tract 
(Mosser et al., 2005). This in sharp contrast to for instance influenza, which has been demonstrated to cause 
more serious epithelial disruption and pathology (Short et al., 2016) Therefore, a reduced antiviral activity 
against RV may be acceptable from a clinical perspective, despite its frequency in causing colds. 
 
3.2 Local and Systemic Anti-inflammatory Effects of EF Extract 
 
Cytokines and chemokines are important immunological players that are complexly regulated during acute 
respiratory tract infections. Their modulation presents an effective means for managing the disease through 
a therapeutic intervention (Johnston, 1997). Suppression of (locally expressed) TNF- α or IL-6 is expected 
to correlate with symptom reduction, whereas anti-virally acting IFN-γ or chemotactic cytokines (e.g. 
MCP-1) are still required to constitute a systemic immune response and their activation might be 
meaningful (Roitt et al., 1998).    
Several in vitro experiments showed down-regulation of TNF-α and IL-6 by EF extract in the airway 
epithelium (local reaction) and this was also confirmed ex vivo in peripheral blood mononuclear cells 
(PBMCs) after peroral ingestion (systemic reaction) (Sharma et al., 2009a/b;  Ritchie et al., 2011). IL-8 was 
down-regulated by EF extract only in epithelial cells in vitro (contributing to the local anti-inflammatory 
effect) but at the same time upregulated systemically by PBMCs ex vivo (Ritchie et al., 2011 and Woelkart 
et al., 2006). Further experiments are required to explain EF’s versatile effects concerning this parameter 
on different cell types. A possible explanation could be variable CB-2 expression patterns (PBMC >> 
epithelial cells), any other yet undefined receptor accounting for differential regulation or systemic 
feedback loop mechanisms.  
Anti-inflammatory effects thus are evident for EF extract, as shown by the local and systemic regulation of 
TNF-α and IL-6 (Sharma et al., 2009a/b; Ritchie et al., 2011; Woelkart et al., 2006). Importantly, this effect 
only applies for endotoxin-free Echinacea, whereas contamination with bacteria produces a contrary 
impact (please refer to Section 1.2 Echinacea Product Heterogeneity). Finally, anti-inflammation appeared 
exclusively upon cellular stimulation with lipopolysaccharide (LPS) or viruses whereas EF extract alone in an 
un-induced setting did not show any effect (Sharma et al., 2009a/b;  Ritchie et al., 2011, Gertsch et al., 
2004). 
 
3.3 Systemic Immuno-modulation by EF-Extract 
 
An intact immune response towards exogenous pathogens depends on further factors, which EF extract is 
able to modulate. Interferon-gamma (IFN-γ), a potent stimulator of antiviral immune defences experienced 
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ex vivo a marked up-regulation when EF extract was administered perorally (Ritchie et al., 2011). In the 
same study, chemotactic cytokines MCP-1 and IL-8 were upregulated. Again, cytokine protein modulation 
was exclusively observed in the presence of viral / bacterial stimuli (LPS), whereas EF alone did not alter 
MCP-1 or IL-8 secretion - neither on epithelial cells nor in PBMC (Gertsch et al., 2004; Sharma et al., 2009). 
Intracellular signalling molecules (STAT or NF-ΚB) and cytokine mRNA may be induced by EF but are not 
translated into biologically active protein. Whether this represents a form of immune cell “priming” remains 
to be determined.  
Effects seen on cytokine production may best be described as immuno-modulation as they not only unfold 
in dependence of absence/presence of pathogens but also of immunological conditions (stress, lack of sleep 
or susceptibility). The concept of Echinacea as immune-modulator is further substantiated by the fact, that 
preventive benefits were primarily observed in subjects with expected weak immune functions as described 
by Jawad (2012). In his meta-analysis, Schapowal et al. (2015) came to the very same conclusion when 
looking at recurrent RTIs and complications.  
Interestingly, EF seems to solely act on cytokine expression whereas the differential blood count did not 
detect any changes in lymphocytes, monocytes, granulocytes or thrombocyte levels even after prolonged 
exposure to EF extract over 4 months (Jawad et al., 2012; Schoop et al., 2006).   
 
3.4 Bioavailability of Alkylamides 
 
It was found that many above observations might result from interaction of alkylamides with the 
endocannabinoid system, in particular CB-2 receptor expressed on immune cells (Gertsch et al., 2004). 
Alkylamide derivatives were shown to permeate cultivated intestinal epithelial cells (Caco-2) and the main 
compound dodeca2E,4E,8Z, 10E/Z tetraenoic acid-isobutylamide (“tetraene”) was found in blood serum 
after peroral administration of different formulations containing EF extract (Matthias et al. 2005, Woelkart 
et al., 2006 and Woelkart et al., 2008). The overall resorption was fast, with Cmax (< 1ng/ml) reached within 
30 min to 1 hour to indicate a first-pass effect - maybe including permeation through mucous membranes. 
The latter however remains to be shown in more detail. Alcohol appears to represent a good carrier and 
we found that Echinaforce (EF) tincture outperformed tablet formulations with respect of the overall 
resorbed amount and time to maximal concentration of tetraene in blood serum. Despite pharmacokinetic 
differences both, EF tincture and tablets attenuated the production of TNF-α to the same extent and 
demonstrated similar bio-activity (Woelkart et al., 2006).  
Bioavailability of immunologically active alkylamides provides a strong linkage between in vitro findings and 




3.5 Clinical Trials on Prevention and Acute Treatment of RTIs 
 
It was an essential part of this PhD work to finally find pre-clinically observed antiviral, anti-inflammatory 
and immune-modulatory effects peaking in clinical efficacy of EF extract.  
In this regard, a comparable antiviral spectrum was identified for EF in vitro and in vivo, showing a high 
specificity against membranous viral pathogens. EF extract proved equivalent to the gold standard 
treatment Oseltamivir for the treatment of influenza. Increased preventive benefits were seen in patients 
with weak immune defences and those in need for effective immune support. It is reasonable to assume 
that the proposed pharmacological actions result in both, preventive and acute treatment benefits. It would 
be interesting to estimate the individual contribution of antiviral, anti-inflammatory and immune-
modulatory effects to the respective treatment situation. Currently, however, this remains a point of 
speculation. 
EF prevented viral infections by 26% overall and by up to 50% in subjects with stress or susceptibility but 
bacterial complications (superinfections) like pneumonia were reduced by as much as 68%. This implicates 
another pharmacological principle in EF, namely a potential activity against bacteria. In vitro tests have 
shown direct inhibition of Streptococcus pyogenes, Haemophilus influenza or Legionellae pneumophilia 
(Sharma et al., 2010). An anti-bacterial mode-of-action is largely unknown and it is questionable whether 
sufficient concentrations of EF compounds are reached in the human organism for physiological relevance. 
Therefore, another – maybe more plausible – explanation for prevention of bacterial RTI complications was 
sought.  
 
3.6 Prevention of Bacterial RTI Complications 
 
Viral infections tend to affect barrier functions of the airway epithelium facilitating subsequent bacterial 
co-infection and development of RTI complications like Pneumonia, Otitis Media or Sinusitis (Matsukura et 
al., 1996). The prevention of viral infections thus has an impact on secondary complications as well because 
barrier functions remain intact (McCullers, 2011). Mechanistically it could be shown that EF even if 
administered after viral attack to epithelial cells reversed the expression of bacteria-binding receptors like 
ICAM-1, PAF-receptor or fibronectin (Vimalanathan R et al., 2017). Otherwise, those receptors would be 
virally induced on surfaces of the airways in high quantities to attract bacteria and facilitate super-
infections. Once more, EF effects unfolded only upon viral activation, whereas under unstimulated 
conditions no significant receptor reduction was observed.   
These very latest findings suggest potential for EF extract beyond the traditional treatment and prevention 
of colds and flu, as a potential alternative to antibiotics which are still routinely used to treat or prevent 
bacterial RTI complications (Cantrell et al, 2002). 
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4.  Implications for Future Research 
Phytochemical characterization of herbal preparations is essential prior to determination of their biological 
activities and clinical benefits. Manufacturing methods may greatly influence the analytical fingerprint and 
consequently therapeutic outcomes. However, any one-way correlation of bio-activities with particular 
chemical markers might be as tempting as misleading because other - yet undiscovered - substances could 
mediate the same effect and / or work synergistically (Wagner and Jurcic, 2011). Plant preparations should 
preferably be regarded in a “holistic” way rather than a mixture of particular chemicals. Importantly, 
influenza viruses are able to develop resistances towards the chemical Oseltamivir but not against the 
multicomponent EF extract (Cheng et al., 2009). Consequently, manufacturers of herbal medicinal products 
should pay prime attention on the production process rather than the concentration of particular chemicals 
in their product (“quality by design” or “the process is the product”). On the example of Echinacea, research 
is still not convincing enough (and will probably never be) to trace down its efficacy to single markers. 
Alkylamides appear to modulate production of TNF-α but show no antiviral potential. The latter activity 
could so far not be attributed to any known marker substance.  
In this context, research on herbal medicinal products remains highly challenging and the comparability 
between differently manufactured products illusive. For this reason, this PhD work concentrated on a single 
Echinacea preparation. The above proposed antiviral, anti-inflammatory and immune-modulatory actions 
principally comply with the current understanding of managing RTIs. The measured bioactivities remained 
stable across different manufacturing lots and production years and thereby proved to be robust. Although 
the chosen research strategy produced convincing results overall, other pharmaceutical activities have not 
been researched yet. Future research should aim to explore Echinacea’s effects on the human microbiome 
or on microbial metagenomics in the gut or airways, which are discussed to have a major impact on the 
human immune system and health. Furthermore, the pharmacology of alkylamides is still not well 
understood. Yet unpublished data showed a wide variety of isobutylamide derivatives in alcoholic extracts 
whereas their individual contribution to immune modulation remains to be determined. On the other hand, 
it would be interesting to elucidate mechanisms and in vivo relevance of antibacterial effects of the extract. 
Ethnopharmacology might provide valuable guidance on the direction of future Echinacea research, 
whereas it is of utmost importance to always refer to the nature of preparation used.  
Maybe the most promising and most convincingly researched potential of EF extract is the unspecific 
activity against a broad range of membranous viruses. The current (2020) Coronavirus (SARS-CoV-2) 
outbreak shows that nature harbours a plethora of pathogens for which the medical armamentarium has 
no solution. Infections can globally spread within weeks and newly developed vaccines or therapies are not 
available fast enough. Readily accessible herbal treatments like EF extract may under real-life conditions 
provide an immediate, affordable and effective therapeutic solution. More in-depth pharmacological 
45 
Doctoral_Work_Roland_Schoop31122020_vs10 
research on how therapeutic benefits manifest might be required to convince health authorities and 
organizations prior to their official recommendation. 
 
5.  Overall Conclusion 
 
This PhD work is based on research that has been carried out and published in the past 10 years (so-called 
PhD by publication). The aim of this doctoral work was to explore in vitro and in vivo pharmacological 
effects, as well as clinical efficacy in prevention and acute treatment of respiratory tract infections for a 
single, phytochemically characterized and standardized Echinacea purpurea extract (Echinaforce®, EF).  
The provided evidence suggests antiviral, anti-inflammatory and immune-modulatory activities, for which 
Echinacea has long been used in tradition. Two clinical studies were conducted to estimate preventive and 
treatment benefits in respiratory tract infections under randomized, double-blind, placebo-/active 
controlled conditions. EF has potential in preventing bacterial complications of initial viral infections 
through regulation of bacteria-binding receptors on epithelial cells.  
The presented work demonstrates, that the applicant has successfully designed and carried out a complete 
research program including pre-clinical, clinical as well as pharmacokinetic studies on Echinacea purpurea. 
Overall, this work substantially contributes to the modern scientific understanding of this medicinal plant 
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